Carlyle Completes Acquisition of Abingworth and Announces Go-forward Leadership Team; Acquisition Expands Global Healthcare Franchise with Leading Life Sciences Investment Expertise
NEW YORK, NY – Global investment firm Carlyle (NASDAQ: CG) and Abingworth, a transatlantic life sciences investment firm with approximately $2 billion in assets under management, have completed Carlyle’s previously announced acquisition of Abingworth. Together, Carlyle and Abingworth will operate across the full risk-return spectrum of life sciences and healthcare investing, from venture capital to buyouts, and continue their longstanding efforts to be an important part of the solution in healthcare.
Steve Wise, Carlyle’s Global Head of Healthcare, said, “We are very excited to officially welcome the Abingworth team to Carlyle. The combination of Carlyle and Abingworth strengthens our global healthcare expertise and ability to invest in innovative businesses that are advancing breakthrough therapies to improve human health.”
At the completion of the transaction, Kurt von Emster assumed the role of Managing Partner and Head of Abingworth Life Sciences, with Bali Muralidhar becoming Managing Partner and Chief Investment Officer of Abingworth. Tim Haines continues as Managing Partner of Abingworth, and Genghis Lloyd-Harris became a Venture Partner at Abingworth.
“Joining forces creates a powerful investment platform across healthcare and life sciences,” said Kurt von Emster. “We are thrilled to take this step together and continue Abingworth’s success in partnership with Carlyle.”
Carlyle and Abingworth have also jointly formed Launch Therapeutics, an operating company that partners with biotech and pharmaceutical companies on the development of late-stage clinical assets to bring lifesaving treatments to market more quickly and efficiently. Launch Therapeutics is led by CEO Anshul Thakral, former Chief Commercial Officer of PPD and a current Carlyle Operating Executive and Abingworth Venture Partner.
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Global Investment Solutions. With $376 billion of assets under management as of June 30, 2022, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 1,900 people in 26 offices across five continents. Further information is available at www.carlyle.com. Follow Carlyle on Twitter @OneCarlyle.
Abingworth is a leading transatlantic life sciences investment firm with approximately $2 billion under management. Abingworth helps transform cutting-edge science into novel medicines by providing capital and expertise to top caliber management teams building world-class companies. Since 1973, Abingworth has invested in 179 life science companies, leading to 74 IPOs and 48 M&As. Abingworth’s therapeutic focused investments fall into three categories: seed and early-stage, development stage and clinical co-development. Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California) and Boston. www.abingworth.com
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include, but are not limited to, statements related to our expectations, estimates, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. You can identify these forward-looking statements by the use of words such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words. Such forward-looking statements are subject to various risks, uncertainties and assumptions. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements and those described under the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC on February 10, 2022, as such factors may be updated from time to time in our periodic filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.
+1 (212) 813-4839